2-(4-methylphenyl)-5-benzoxazolecarboxylate | 63556-98-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(4-methylphenyl)-5-benzoxazolecarboxylate
• 英文别名: 2-(4-methylphenyl)-5-benzoxazolecarboxylic acid；2-p-tolylbenzo[d]oxazole-5-carboxylic acid；2-p-tolyl-benzooxazole-5-carboxylic acid；2-(4-methylphenyl)-1,3-benzoxazole-5-carboxylic acid
• CAS: 63556-98-9
• 化学式: C₁₅H₁₁NO₃
• mdl: MFCD10024010
• 分子量: 253.257
• InChiKey: RCJFUQXKOKXYMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.066
• 拓扑面积：
  63.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-methylphenyl)-5-benzoxazolecarboxylate 以 氯化亚砜 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-(4-methylphenyl)-5-benzoxazolecarbonyl chloride
  参考文献：
  名称：

  US4029670

  摘要：

  公开号：
• 作为产物：
  描述：

  methyl 2-p-tolylbenzo[d]oxazole-5-carboxylate 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 生成 2-(4-methylphenyl)-5-benzoxazolecarboxylate
  参考文献：
  名称：

  US4029670

  摘要：

  公开号：

文献信息

• METHODS FOR TREATING SPINAL MUSCULAR ATROPHY
  申请人：Paushkin Sergey V.

  公开号：US20110086833A1

  公开（公告）日：2011-04-14

  The present invention provides nucleic acid constructs, methods for identifying and validating compounds that increase the inclusion of exon 7 of SMN2 into mRNA transcribed from the SMN2 gene, compounds and pharmaceutical compositions that increase levels of SMN protein produced from the SMN2 gene, and methods for use thereof in treating of SMA.

  本发明提供了核酸构建物，用于识别和验证增加SMN2基因转录的mRNA中exon 7包含量的化合物的方法，增加从SMN2基因产生的SMN蛋白水平的化合物和药物组合物，以及在SMA治疗中使用它们的方法。
• [EN] DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY<br/>[FR] COMBINAISONS DE MÉDICAMENTS POUR LE TRAITEMENT DE LA DYSTROPHIE MUSCULAIRE DE DUCHENNE
  申请人：SUMMIT CORP PLC

  公开号：WO2009019504A1

  公开（公告）日：2009-02-12

  Combinations comprising (or consisting essentially of) one or more compounds of formula (1) with one or more ancillary agents, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia using the combinations.

  本发明涉及与一种或多种公式（1）化合物和一种或多种辅助剂组成的组合物（或基本上由其组成的组合物），以及制备该组合物的方法，以及该组合物的多种治疗用途。还提供了含有该组合物的制药组合物以及使用该组合物治疗杜氏肌肉萎缩症，贝克肌肉萎缩症或消瘦症的方法。
• Bichromophoric benzoxazole ultraviolet stabilizers
  申请人：Eastman Kodak Company

  公开号：US04169837A1

  公开（公告）日：1979-10-02

  The invention relates to bichromophoric heterocyclic ester compounds which have been found to be effective ultraviolet stabilizers. The invention also relates to ultraviolet degradable organic compositions containing a stabilizing amount of these bichromophoric heterocyclic ester compositions to prevent such degradation. These stabilizers are effective in the presence of other additives commonly employed in polymeric compositions including, for example, pigments, colorants, fillers, reinforcing agents and the like. These ultraviolet stabilizers may also be incorporated into the organic compositions in the polymer melt or dissolved in the polymer dope, coated on the exterior of the molded article, film or extruded fiber.

  本发明涉及一种双色团杂环酯化合物，发现其具有有效的紫外线稳定剂作用。本发明还涉及含有稳定量的这些双色团杂环酯化合物的紫外线降解有机组合物，以防止这种降解。这些稳定剂在聚合物组合物中常用的其他添加剂，包括颜料、染料、填充剂、增强剂等存在时也是有效的。这些紫外线稳定剂也可以在聚合物熔融中或溶解在聚合物溶液中被纳入有机组合物中，涂覆在成型物、薄膜或挤出纤维的外部。
• Polychromophoric heterocyclic ultraviolet stabilizers
  申请人：Eastman Kodak Company

  公开号：US04029670A1

  公开（公告）日：1977-06-14

  The invention relates to bichromophoric heterocyclic ester compounds which have been found to be effective ultraviolet stabilizers. The invention also relates to ultraviolet degradable organic compositions containing a stabilizing amount of these bichromophoric heterocyclic ester compositions to prevent such degradation. These stabilizers are effective in the presence of other additives commonly employed in polymeric compositions including, for example, pigments, colorants, fillers, reinforcing agents and the like. These ultraviolet stabilizers may also be incorporated into the organic compositions in the polymer melt or dissolved in the polymer dope, coated on the exterior of the molded article, film or extruded fiber.

  本发明涉及一种具有双色性杂环酯化合物的紫外线稳定剂，已发现其具有高效的紫外线稳定性。本发明还涉及含有这些双色性杂环酯化合物的稳定剂量的紫外线降解有机组合物，以防止这种降解。这些稳定剂在聚合物组合物中常用的其他添加剂存在下也具有高效，包括颜料、着色剂、填充剂、增强剂等。这些紫外线稳定剂也可以在聚合物熔融中或溶解在聚合物溶液中，涂覆在成型物、薄膜或挤出纤维的外部。
• TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
  申请人：Wynne Graham Michael

  公开号：US20090075938A1

  公开（公告）日：2009-03-19

  There are disclosed compound of Formula (1): A 1 , A 2 , A 3 and A 4 which may be the same or different, represent N or CR 1 , X is a divalent group selected from O, S(O) n , C═W, NR 4 , NC(═O)R 5 and CR 6 R 7 , W is O, S, NR 20 , Y is N or CR 8 , one of R 4 , R 5 , R 6 , R 8 , R 9 and NR 20 represents -L-R 3 , in which L is a single bond or a linker group, additionally, R 1 , R 3 -R 9 , which may be the same or different, independently represent hydrogen or a substituent and R 20 represents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO 2 , NR 30 R 31 , in which R 30 and R 31 , which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of R 30 and R 31 may represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent pair of A 1 -A 4 each represent CR 1 , then the adjacent carbon atoms, together with their substituents may form a ring B, when X is CR 6 R 7 , R 6 and R 7 , together with the carbon atom to which they are attached may form a ring C, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia.

  公式（1）的化合物被揭示：A1，A2，A3和A4，它们可以相同或不同，代表N或CR1，X是从O，S（O）n，C═W，NR4，NC（═O）R5和CR6R7中选择的二价基团，W是O，S，NR20，Y是N或CR8，R4，R5，R6，R8，R9和NR20中的一个表示-L-R3，在其中L是单键或连接基团，此外，R1，R3-R9可以相同或不同，独立地表示氢或取代基，R20表示氢，羟基，可以用芳基取代的烷基，可以用芳基取代的烷氧基，芳基，CN，可以用芳基取代的烷氧基，可以用芳基取代的芳氧基，可以用取代基取代的烷酰基，可以用取代基取代的芳酰基，NO2，NR30R31，在其中R30和R31可以相同或不同，表示氢，可选地取代的烷基或可选地取代的芳基；此外，R30和R31中的一个可以表示可选地取代的烷酰基或可选地取代的芳酰基，n表示从0到2的整数，另外，当相邻的A1-A4中的一对表示CR1时，那么相邻的碳原子及其取代基可以形成环B，当X为CR6R7时，R6和R7与它们附着的碳原子一起可以形成环C，或其药学上可接受的盐，在制造用于治疗和/或预防杜氏肌萎缩症，贝克肌萎缩症或消瘦症的药物时使用。